A number of procedures have been investigated for the treatment of urinary incontinence, including pelvic floor muscle exercises, behavioral therapy, sacral nerve stimulation, pelvic floor stimulation, surgery, and radiofrequency energy.
InterStim Continence Control Therapy is sacral nerve stimulation that involves the implantation, into the lower back, of electrical leads that are in contact with the sacral nerve root. The wire leads extend through an incision in the abdomen and are connected to an inserted pulse generator to deliver controlled electrical impulses. The physician programs the pulse generator and the individual is able to switch the pulse generator on and off.
Percutaneous tibial nerve stimulation with Urgent® PC by Uroplasty involves the placement of a fine needle electrode into the lower, inner aspect of the leg, near the tibial nerve. The needle electrode is connected to pulse generator that delivers an electrical pulse to the tibial nerve that travels to the sacral plexus. The sacral plexus is responsible for regulating bladder and pelvic floor function. The treatment protocol is for 12 treatments, once a week.
An artificial urinary sphincter is a device that involves an inflatable cuff that fits around the urethra. A balloon regulates the pressure of the cuff and a bulb controls inflation and deflation of the cuff. The balloon is surgically placed and the control pump is typically placed in the scrotum for men and the labia for women. The cuff is inflated to prevent incontinence and deflated to allow the patient to urinate.
Injectable bulking agents may be effective in decreasing urinary incontinence in men and women with intrinsic sphincter disorder. The bulking agent increases bladder-outlet resistance and/or increases urethral length. The agent is injected into the submucosal tissues of the urethra or bladder neck and/or into the tissues adjacent to the urethra. The injections increase tissue bulk, thereby increasing outlet resistance.
Pelvic floor stimulation involves the electrical stimulation of pelvic floor muscles using either a probe wired to a device for controlling the electrical stimulation, or extracorporeal pulse magnetic innervation.
Innova is a commonly used electrical stimulator that consists of a battery-operated stimulator with a vaginal or rectal electrode. Treatment is performed in the privacy of the patient's home. Extracorporeal Magnetic Innervation Therapy (ExMI) is a noninvasive conservative treatment for urinary incontinence in adult women. This therapy utilizes a changing magnetic field to induce electrical depolarization of nerves and muscles of the pelvic floor. The use of this device consists of a patient sitting fully clothed in a specialized chair in which the perineum rests on the central axis of a pulsing magnetic field.
Radiofrequency energy has been investigated as a technique to shrink and stabilize the endopelvic fascia or the urethra. The SURx Transvaginal System is a radiofrequency device that has been specifically designed as a transvaginal treatment of urinary stress incontinence. The Renessa System is a non-surgical radiofrequency device that uses a balloon catheter system to deliver low temperature radiofrequency energy to the submucosa of the bladder neck and urethra. The controlled heat applied by a radiofrequency device, causes the tissue in the lower urinary tract to become firmer after healing and therefore, increases resistance to involuntary leakage.
II. Criteria: CWQI HCS-0067A and B
A. Moda Health covers 1 or more of the following: a. Sacral nerve stimulation/InterStim Continence Control Therapy (CWQI: HCS-0067B) will be covered to plan benefits for the treatment of urinary incontinence when 1 or more of the following criteria are met: i. A trial of sacral nerve stimulation is medically indicated when ALL of the following are met: 1. Documentation of 12 months of urinary incontinence that includes urge incontinence, nonobstructive urinary retention, or symptoms of urgency/frequency severe enough that the condition has resulted in significant disability (the frequency and/or severity of symptoms are limiting the member's ability to participate in daily activities) 2. Patient must be refractory to three month trial conventional therapy (documented behavioral, pharmacologic and/or surgical corrective therapy) and be an appropriate surgical candidate such that implantation with anesthesia can occur.) ii. Patient has urinary incontinence resulting from intrinsic sphincter deficiency that is refractory to 12 months conservative management (e.g. Kegel exercises, biofeedback, electrical stimulation, and/or pharmacotherapies); or iii. The member has stress incontinence for six months and ALL of the following:
1. No other causes of stress incontinence (urinary tract infection, etc.) 2. Activities of daily living are limited by the stress incontinence iv. Request for injection of periurethral bulking agents for UI is considered experimental and investigational for neurogenic bladder and all other indications v. Prior to collagen implant therapy, a skin test for collagen sensitivity must be administered and evaluated over a 4 week period. No skin test is required for the carbon-coated beads vi. Request is for 5 injection procedures only. f. Request for continuation of treatment will be covered for 1 or more of the following:
i. Percutaneous tibial nerve stimulation will be covered when All of the following criteria are met: 1. Documentation of improvement of incontinence after 12 treatments ii. Periurethral Injections of Bulking Agents will be covered when All of the following criteria are met: 1. Incontinence improves after 3 treatments with bulking agents NOTE: If incontinence does not improve after 3 treatments with bulking agents, treatment is considered ineffective and further treatment with bulking agents is not considered medically necessary. g. The requested procedure does NOT include ALL of the following as their effectiveness has not been established. i. Radiofrequency energy (SURx, Renessa System, etc.) for the treatment of stress urinary incontinence. ii. The Genityte procedure (laser therapy) iii. Pudendal nerve stimulation iv. Autologous myoblast transplantation v. Autologous muscle-derived cell therapy vi. Collagen porcine dermis mesh vii. Stem cell therapy viii. The extraurethral non-circumferential retropubic adjustable compression devices (ProACT Therapy System, Uromedica, Inc.) ix. Radiofrequency micro-remodeling with SURs System (paraurethral or transvaginal) x. The Neocontrol system, which uses extracorporeal magnetic innervation (ExMI) III. Information Submitted with the Prior Authorization Request:
1. Chart notes from the treating physician documenting history of incontinence and treatments 2. For review of sacral nerve stimulators, 12 months of chart notes from the treating physician are required, documenting that the above criteria are met.
IV. CPT or HCPC codes covered:
Codes Description Medicare coverage for outpatient (Part B) drugs is outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals. In addition, National Coverage Determination (NCD) and Local Coverage Determinations (LCDs) may exist and compliance with these policies is required where applicable. They can be found at: http://www.cms.gov/medicare-coverage-database/search/advanced-search.aspx. Additional indications may be covered at the discretion of the health plan.
Medicare Part B Covered Diagnosis Codes (applicable to existing NCD/LCD):
